ZAMBA: Zoledronic Acid for Modic Back Pain.
EU CTIS ID: 2024-517345-14-00
What this study is testing
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- LBP of > 50% of days for > 6 months duration in the area below the 12th rib and above the gluteal folds with: ODI-score ≥ 30 and/or Numerical Rating Scale (NRS) pain intensity score of ≥ 5 (mean of three NRS scales; current LBP, the worst LBP within the last 2 weeks, and usual/mean LBP within the last 2 weeks), MC containing type 1 at any level Th12-S1 and with craniocaudal height ≥ 10% of vertebral body height and diameter > 5 mm.
You likely can't join if
- Age <18 and > 65 years and for women with childbearing potential
The study team makes the final eligibility decision.
Where it's taking place
- Norway
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Norway. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.